Inovio Pharmaceuticals (NASDAQ:INO) Lowered to Hold Rating by Zacks Research

Zacks Research downgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a strong-buy rating to a hold rating in a research note published on Wednesday,Zacks.com reports.

Several other analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Piper Sandler began coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, July 9th. They set an “overweight” rating and a $5.00 target price on the stock. Oppenheimer dropped their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 14th. HC Wainwright reissued a “neutral” rating and set a $3.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, August 14th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $5.00 target price on shares of Inovio Pharmaceuticals in a research report on Wednesday, May 14th. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Inovio Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $8.80.

Inovio Pharmaceuticals Trading Up 1.5%

NASDAQ:INO opened at $2.79 on Wednesday. The company has a market cap of $148.26 million, a PE ratio of -1.07 and a beta of 1.62. Inovio Pharmaceuticals has a twelve month low of $1.30 and a twelve month high of $7.00. The company’s 50 day moving average is $1.73 and its two-hundred day moving average is $1.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, August 12th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.02. As a group, analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current fiscal year.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently made changes to their positions in INO. Nomura Holdings Inc. acquired a new position in shares of Inovio Pharmaceuticals in the 1st quarter valued at $28,000. Freedom Investment Management Inc. acquired a new position in shares of Inovio Pharmaceuticals in the 1st quarter valued at $31,000. Alpine Global Management LLC acquired a new position in shares of Inovio Pharmaceuticals in the 4th quarter valued at $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the period. Finally, Catalyst Funds Management Pty Ltd acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $35,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.